Dexpramipexole
- Generic Name
- Dexpramipexole
- Drug Type
- Small Molecule
- Chemical Formula
- C10H17N3S
- CAS Number
- 104632-28-2
- Unique Ingredient Identifier
- WI638GUS96
- Background
Dexpramipexole is under investigation in clinical trial NCT01511029 (Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate)).
Dexpramipexole and Warfarin Drug Drug Interaction (DDI) Study
- First Posted Date
- 2012-05-14
- Last Posted Date
- 2014-11-25
- Lead Sponsor
- Knopp Biosciences
- Target Recruit Count
- 15
- Registration Number
- NCT01597310
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Dexpramipexole and Cimetidine Drug Drug Interaction (DDI)
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- First Posted Date
- 2012-02-22
- Last Posted Date
- 2014-11-25
- Lead Sponsor
- Knopp Biosciences
- Target Recruit Count
- 14
- Registration Number
- NCT01536249
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate)
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- First Posted Date
- 2012-01-18
- Last Posted Date
- 2014-11-25
- Lead Sponsor
- Knopp Biosciences
- Target Recruit Count
- 68
- Registration Number
- NCT01511029
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Dexpramipexole SAD/MAD Study
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- First Posted Date
- 2011-10-10
- Last Posted Date
- 2014-11-25
- Lead Sponsor
- Knopp Biosciences
- Target Recruit Count
- 63
- Registration Number
- NCT01449578
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Dexpramipexole Renal PK Study
- Conditions
- Amyotrophic Lateral SclerosisRenal Insufficiency
- Interventions
- First Posted Date
- 2011-08-26
- Last Posted Date
- 2014-11-25
- Lead Sponsor
- Knopp Biosciences
- Target Recruit Count
- 36
- Registration Number
- NCT01424176
- Locations
- 🇺🇸
Research Site, Brooklyn Center, Minnesota, United States
Phase 3 Study of Dexpramipexole in ALS
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-01-21
- Last Posted Date
- 2021-06-07
- Lead Sponsor
- Knopp Biosciences
- Target Recruit Count
- 942
- Registration Number
- NCT01281189
- Locations
- 🇧🇪
AZ St-Lucas, Gent, Belgium
🇧🇪UZ Leuven, Leuven, Belgium
🇺🇸Emory University, Atlanta, Georgia, United States
Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)
- First Posted Date
- 2009-07-02
- Last Posted Date
- 2021-08-16
- Lead Sponsor
- Knopp Biosciences
- Target Recruit Count
- 74
- Registration Number
- NCT00931944
- Locations
- 🇺🇸
SUNY Upstate Medical University, Syracuse, New York, United States
🇺🇸Penn State Hershey Medical Center, Hershey, Pennsylvania, United States
🇺🇸Columbia University, Lou Gehrig MDA/ALS Research Center, New York, New York, United States
Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS)
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- First Posted Date
- 2008-03-31
- Last Posted Date
- 2021-07-08
- Lead Sponsor
- Knopp Biosciences
- Target Recruit Count
- 194
- Registration Number
- NCT00647296
- Locations
- 🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
🇺🇸Drexel University College Of Medicine, Philadelphia, Pennsylvania, United States
🇺🇸University of Washington, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.